# NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

> **NCT04781309** · EARLY_PHASE1 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 12 (actual)

## Conditions studied

- Progressive Multifocal Leukoencephalopathy

## Interventions

- **DRUG:** NT-I7

## Key facts

- **NCT ID:** NCT04781309
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-05
- **Primary completion:** 2025-11-07
- **Final completion:** 2025-11-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781309, "NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04781309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*